Collective Molecular Activities of the Plant: Genipa Americana
Example Image
PLANiTS DNA barcode
Taxonomic Information
Plant ID: NPO17824
Plant Latin Name: Genipa Americana
Taxonomy Genus: Genipa
Taxonomy Family: Rubiaceae
Plant External Links:
NCBI TaxonomyDB:
58486
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Compounds Summary
Overview of Ingredients
46 All known Ingredients in Total
Unique ingredients have been isolated from this plant.Plant-Ingredients Associations were manually curated from publications or collected from other databases.
35 Ingredients with Acceptable Bioavailablity
Unique ingredients exhibit acceptable human oral bioavailablity, according to the criteria of SwissADME [PMID: 28256516] and HobPre [PMID: 34991690]. The criteria details:SwissADME: six descriptors are used by SwissADME to evaluate the oral bioavailability of a natural product:
☑ LIPO(Lipophility): -0.7 < XLOGP3 < +5.0
☑ SIZE: 150g/mol < MW < 500g/mol
☑ POLAR(Polarity): 20Ų < TPSA < 130Ų
☑ INSOLU(Insolubility): -6 < Log S (ESOL) < 0
☑ INSATU(Insaturation): 0.25 < Fraction Csp3 < 1
☑ FLEX(Flexibility): 0 < Num. rotatable bonds < 9
If 6 descriptors of a natural plant satisfy the above rules, it will be labeled high HOB.
HobPre: A natural plant ingredient with HobPre score >0.5 is labeled high human oral availability (HOB)
40 Ingredients with experimental-derived Activity
Unique ingredients have activity data available.Ingredient Structrual Cards
Ingredient ID: NPC484026
Ingredient ID: NPC484024
Ingredient ID: NPC484023
Ingredient ID: NPC484022
Ingredient ID: NPC484021
Ingredient ID: NPC484020
Ingredient ID: NPC484019
Ingredient ID: NPC484018
Ingredient ID: NPC484017
Ingredient ID: NPC484016
Ingredient ID: NPC484015
Ingredient ID: NPC484014
Ingredient ID: NPC484013
Ingredient ID: NPC484012
Ingredient ID: NPC484011
Ingredient ID: NPC484010
Ingredient ID: NPC484009
Ingredient ID: NPC484008
Ingredient ID: NPC484007
Ingredient ID: NPC484006
Ingredient ID: NPC484005
Ingredient ID: NPC484003
Ingredient ID: NPC483999
Ingredient ID: NPC482656
Ingredient ID: NPC481588
Ingredient ID: NPC481564
Ingredient ID: NPC46861
Ingredient ID: NPC39019
Ingredient ID: NPC362157
Ingredient ID: NPC317177
Ingredient ID: NPC296163
Ingredient ID: NPC29246
Ingredient ID: NPC284635
Ingredient ID: NPC255677
Ingredient ID: NPC241911
Ingredient ID: NPC234304
Ingredient ID: NPC222062
Ingredient ID: NPC211455
Ingredient ID: NPC199994
Ingredient ID: NPC188717
Ingredient ID: NPC184453
Ingredient ID: NPC13171
Ingredient ID: NPC118761
Ingredient ID: NPC114788
Ingredient ID: NPC113219
Ingredient ID: NPC110157
Classification of Human Proteins Collectively Targeted by the Plant
*The classification criteria of Drug Transporter (DTP), CYP450 are referred to DrugMap. Other molecular targets in CMAUP are classified as therapeutic targets.
.
Detailed Information of Target Proteins
| Target Type | Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|---|
| Therapeutic Target | Enzyme | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Therapeutic Target | Isomerase | PIN1 | Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Q13526 | CHEMBL2288 |
| Therapeutic Target | Membrane receptor | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
| Therapeutic Target | Methyl-lysine/arginine binding protein | SMN1 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Therapeutic Target | Nuclear hormone receptor subfamily 1 | RARB | Retinoic acid receptor beta | P10826 | CHEMBL2008 |
| Therapeutic Target | Nuclear hormone receptor subfamily 1 | RARG | Retinoic acid receptor gamma | P13631 | CHEMBL2003 |
| Therapeutic Target | Nuclear hormone receptor subfamily 1 | RORA | Nuclear receptor ROR-alpha | P35398 | CHEMBL5868 |
| Therapeutic Target | Nuclear hormone receptor subfamily 1 | RORB | Nuclear receptor ROR-beta | Q92753 | CHEMBL3091268 |
| Therapeutic Target | Nuclear hormone receptor subfamily 1 | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
| Therapeutic Target | Nuclear hormone receptor subfamily 1 | RARA | Retinoic acid receptor alpha | P10276 | CHEMBL2055 |
| Therapeutic Target | Nuclear hormone receptor subfamily 2 | RXRA | Retinoid X receptor alpha | P19793 | CHEMBL2061 |
| Therapeutic Target | Nuclear hormone receptor subfamily 2 | RXRG | Retinoid X receptor gamma | P48443 | CHEMBL2004 |
| Therapeutic Target | Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Therapeutic Target | Small molecule receptor (family A GPCR) | HTR2B | Serotonin 2b (5-HT2b) receptor | P41595 | CHEMBL1833 |
| Therapeutic Target | Transcription factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Clinical Trials Summary
Overview
Clinical trials associated with plant from natural product (NP) & plant level:
| Clinical trials type | Number of clinical trials | |
|---|---|---|
 NP level | 147 | |
Clinical trial details
| NCT ID | Title | Condition | Form in clinical use | Associated by plant or compound |
|---|---|---|---|---|
| NCT03999684 | A Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma | adenoid cystic carcinoma | Tretinoin (NPC317177) | NP level |
| NCT00867672 | Study of Decitabine Alone or in Combination With Valproic Acid and All-trans Retinoic Acid in Acute Myeloid Leukemia | acute myeloid leukemia | Tretinoin (NPC317177) | NP level |
| NCT02200978 | A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia | acute promyelocytic leukemia | Tretinoin (NPC317177) | NP level |
| NCT01915758 | W0265-104: A Single-Center, Evaluator-Blinded, Randomized, Placebo-Controlled, Phase 1 Clinical Trial Evaluating the Photoallergic Potential of Topically Applied Clindamycin Phosphate 1.0% and Tretinoin 0.025% (CT Gel) in Healthy Volunteers | acne | Tretinoin (NPC317177) | NP level |
| NCT03356080 | DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess | acute myeloid leukemia;myelodysplastic syndrome | Tretinoin (NPC317177) | NP level |
| NCT03200847 | Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma | melanoma | Tretinoin (NPC317177) | NP level |
| NCT00669071 | Treatment w/ Tri-Luma® Cream & Intense Pulsed Light (IPL) vs a Mild Inactive Control Cream & Intense Pulsed Light (IPL) in Melasma | freckles | Tretinoin (NPC317177) | NP level |
| NCT00714714 | Evaluation of Irritation That Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face. | acne | Tretinoin (NPC317177) | NP level |
| NCT00005969 | Liposomal Tretinoin in Treating Patients With Recurrent or Refractory Hodgkin's Disease | lymphoma | Tretinoin (NPC317177) | NP level |
| NCT00002479 | Tretinoin in Treating Patients With Mycosis Fungoides or Sezary Syndrome | lymphoma | Tretinoin (NPC317177) | NP level |
| NCT00952523 | Evaluation of Irritation That Potentially Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face | acne | Tretinoin (NPC317177) | NP level |
| NCT04113863 | Evaluation of ATRA Activity in Combination With Anastrozole in Pre-operative Phase of Operable Early Breast Cancer | breast neoplasm | Tretinoin (NPC317177) | NP level |
| NCT04793919 | Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia | acute promyelocytic leukemia | Tretinoin (NPC317177) | NP level |
| NCT00002658 | Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia | leukemia | Tretinoin (NPC317177) | NP level |
| NCT02261779 | Phase I/II Trial of ATRA and TCP in Patients With Relapsed or Refractory AML and no Intensive Treatment is Possible | acute myeloid leukemia | Tretinoin (NPC317177) | NP level |
| NCT00136461 | A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) | acute myeloid leukemia;myelodysplastic syndrome | Tretinoin (NPC317177) | NP level |
| NCT00533169 | ZD6474 Alone and in Combination With Retinoic Acid in Pediatric Neuroblastoma | neuroblastoma | Tretinoin (NPC317177) | NP level |
| NCT00143975 | Gemtuzumab Ozogamicin in Combination With A-HAM in Refractory AML (GO-A-HAM) | acute myeloid leukemia | Tretinoin (NPC317177) | NP level |
| NCT00151255 | All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia | acute myeloid leukemia | Tretinoin (NPC317177) | NP level |
| NCT00180128 | AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia | acute promyelocytic leukemia | Tretinoin (NPC317177) | NP level |
| NCT04303169 | Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02) | melanoma | Tretinoin (NPC317177) | NP level |
| NCT04700176 | A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma | multiple myeloma | Tretinoin (NPC317177) | NP level |
| NCT00017225 | Chemotherapy and Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma | neuroblastoma | Tretinoin (NPC317177) | NP level |
| NCT00717652 | Efficiency And Safety Of Association Arbutin, Triamcinolone And Tretinoin In Treatment Of Melasma | freckles | Tretinoin (NPC317177) | NP level |
| NCT01522456 | Split-face Tolerability Comparison Between Adapalene-Benzoyl Peroxide Gel Versus Tretinoin Gel | acne | Tretinoin (NPC317177) | NP level |
| NCT00006239 | Phenylbutyrate and Tretinoin in Treating Patients With Hematologic Cancer | myelodysplastic/myeloproliferative disease;leukemia;myelodysplastic syndrome | Tretinoin (NPC317177) | NP level |
| NCT00005825 | Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer | lung cancer | Tretinoin (NPC317177) | NP level |
| NCT02620813 | De Novo Lipogenesis of Sebaceous Glands in Acne | acne | Tretinoin (NPC317177) | NP level |
| NCT00002701 | Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia | leukemia | Tretinoin (NPC317177) | NP level |
| NCT02497833 | Retinoic Acid Supplementation and Subjects With Hypercholesterolemia | Hypercholesterolemia | Tretinoin (NPC317177) | NP level |
| NCT00003934 | Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia | acute promyelocytic leukemia | Tretinoin (NPC317177) | NP level |
| NCT00469183 | Assessment of Atrophogenic Potential of Triple Combination Cream for Treatment of Melasma | freckles | Tretinoin (NPC317177) | NP level |
| NCT01667263 | The Combination of ATRA and Danazol as Second-line Treatment in Adult Immune Thrombocytopenia | autoimmune thrombocytopenia | Tretinoin (NPC317177) | NP level |
| NCT00003656 | Tretinoin Plus Interferon Alfa in Treating Patients With Metastatic Kidney Cancer | kidney cancer | Tretinoin (NPC317177) | NP level |
| NCT00962767 | Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission | acute myeloid leukemia | Tretinoin (NPC317177) | NP level |
| NCT00408278 | Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005) | acute promyelocytic leukemia | Tretinoin (NPC317177) | NP level |
| NCT01882127 | All-Trans Retinoic Acid (ATRA) Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP) | autoimmune thrombocytopenic purpura | Tretinoin (NPC317177) | NP level |
| NCT00482833 | Phase III Trial in Acute Promyelocytic Leukemia Patients | leukemia | Tretinoin (NPC317177) | NP level |
| NCT00005863 | Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia | leukemia;myelodysplastic syndrome;myeloproliferative disorder | Tretinoin (NPC317177) | NP level |
| NCT01456468 | Combination Therapy With Ursodeoxycholic Acid (UDCA) and All-Trans Retinoic Acid (ATRA) for Treatment of Primary Sclerosing Cholangitis | sclerosing cholangitis | Tretinoin (NPC317177) | NP level |
| NCT00007631 | Determine the Efficacy of Topical Tretinoin Cream for the Prevention of Nonmelanoma Skin Cancer | basal cell carcinoma;squamous cell carcinoma | Tretinoin (NPC317177) | NP level |
| NCT02339740 | Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia | acute promyelocytic leukemia | Tretinoin (NPC317177) | NP level |
| NCT01161550 | Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AML | acute myeloid leukemia | Tretinoin (NPC317177) | NP level |
| NCT00891982 | A Clinical Study to Evaluate the Tolerability of a Topical Antibiotic and Retinoid Used in a Combined Regimen With a BPO Wash | acne | Tretinoin (NPC317177) | NP level |
| NCT00100906 | Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer | kidney cancer | Tretinoin (NPC317177) | NP level |
| NCT02712905 | An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies | hematopoietic and lymphoid cell neoplasm | Tretinoin (NPC317177) | NP level |
| NCT01575691 | Phase II 5-Azacytidine Plus VPA Plus ATRA | acute myeloid leukemia;myelodysplastic syndrome | Tretinoin (NPC317177) | NP level |
| NCT03572387 | A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment | prostate adenocarcinoma | Tretinoin (NPC317177) | NP level |
| NCT03433378 | To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.05% and RLD in the Treatment of Acne Vulgaris | acne | Tretinoin (NPC317177) | NP level |
| NCT04883736 | A Study Comparing Tretinoin Gel Microsphere, 0.1% and RETIN-A MICRO ® Gel Microsphere, 0.1% in the Treatment of Acne Vulgaris | acne | Tretinoin (NPC317177) | NP level |
| NCT00175812 | Differentiation Induction in Acute Myelogenous Leukemia | acute myeloid leukemia | Tretinoin (NPC317177) | NP level |
| NCT04919369 | All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer | non-small cell lung carcinoma | Tretinoin (NPC317177) | NP level |
| NCT03259516 | Nivolumab With Chemotherapy in Refractory MDS | myelodysplastic syndrome | Tretinoin (NPC317177) | NP level |
| NCT00689117 | A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational Product Called CT Gel | acne | Tretinoin (NPC317177) | NP level |
| NCT00276601 | Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia | leukemia | Tretinoin (NPC317177) | NP level |
| NCT03359174 | An Efficacy Trial of Low Dose All-trans Retinoic Acid in Patients With Primary Sclerosing Cholangitis | sclerosing cholangitis | Tretinoin (NPC317177) | NP level |
| NCT02278861 | Oral Isotretinoin Versus Topical Tretinoin for Actinic Keratosis | actinic keratosis | Tretinoin (NPC317177) | NP level |
| NCT00919555 | Combination Therapy in Amyotrophic Lateral Sclerosis (ALS) | amyotrophic lateral sclerosis | Tretinoin (NPC317177) | NP level |
| NCT01125930 | Atralin Gel for the Treatment of Rosacea | rosacea | Tretinoin (NPC317177) | NP level |
| NCT00599937 | APL93: Timing of CxT and Role of Maintenance | acute promyelocytic leukemia | Tretinoin (NPC317177) | NP level |
| NCT01275274 | Retinoids in ANCA Small Vessel Vasculitis: Silencing Autoantigens | anti-neutrophil antibody associated vasculitis | Tretinoin (NPC317177) | NP level |
| NCT02641782 | NB2013-HR German (GPOH) / Dutch (DCOG) Trial | neuroblastoma | Tretinoin (NPC317177) | NP level |
| NCT00841776 | Comparative Antimicrobial Efficacy of Two Topical Acne Therapies for the Treatment of Facial Acne | acne | Tretinoin (NPC317177) | NP level |
| NCT02688140 | Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia | acute promyelocytic leukemia | Tretinoin (NPC317177) | NP level |
| NCT00000621 | Feasibility of Retinoic Acid Treatment in Emphysema (FORTE) | emphysema | Tretinoin (NPC317177) | NP level |
| NCT04548349 | Profiling the Skin Microbiome in Response to Altreno in Acne Patients | acne | Tretinoin (NPC317177) | NP level |
| NCT02020161 | Clinical Guidelines for APL Treatment | acute promyelocytic leukemia | Tretinoin (NPC317177) | NP level |
| NCT04305041 | Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02) | melanoma | Tretinoin (NPC317177) | NP level |
| NCT00601796 | Vaccine Therapy, Tretinoin, and Cyclophosphamide in Treating Patients With Metastatic Lung Cancer | lung cancer | Tretinoin (NPC317177) | NP level |
| NCT01985477 | Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma | multiple myeloma | Tretinoin (NPC317177) | NP level |
| NCT04241276 | Phase IIb Randomised Trial of ATRA in a Novel Drug Combination for Pancreatic Cancer | pancreatic carcinoma | Tretinoin (NPC317177) | NP level |
| NCT04282668 | A Study of TAS1440 With ATRA in Subjects With r/r AML | acute myeloid leukemia | Tretinoin (NPC317177) | NP level |
| NCT01111994 | Efficacy & Safety of Clindamycin and Tretinoin in Acne | acne | Tretinoin (NPC317177) | NP level |
| NCT01409161 | Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia | acute promyelocytic leukemia | Tretinoin (NPC317177) | NP level |
| NCT04324411 | Sirolimus Combined With ATRA for the Treatment of Auto-Immune Anemia | anemia | Tretinoin (NPC317177) | NP level |
| NCT00866918 | Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia | acute promyelocytic leukemia | Tretinoin (NPC317177) | NP level |
| NCT01237808 | Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation | acute myeloid leukemia | Tretinoin (NPC317177) | NP level |
| NCT05281965 | A Clinical Study Evaluating the Efficacy and Safety of Retinoic Acid in Patients With 15q11-q13 Duplication Syndrome | autism | Tretinoin (NPC317177) | NP level |
| NCT00975312 | Solar Lentigines Treatment With the Triple Combination Cream | lentigo | Tretinoin (NPC317177) | NP level |
| NCT00439673 | PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS | myelodysplastic syndrome | Tretinoin (NPC317177) | NP level |
| NCT02942758 | Low-dose AZA, Pioglitazone, ATRA Versus Standard-dose AZA in Patients >=60 Years With Refractory AML | acute myeloid leukemia | Tretinoin (NPC317177) | NP level |
| NCT05438875 | The Combination of ATRA and Eltrombopag as the Treatment of Steroid-resistant/Relapse ITP Based on MSC-C5b-9 | autoimmune thrombocytopenic purpura | Tretinoin (NPC317177) | NP level |
| NCT05297123 | Treatment of Acute Myeloid Leukemia With Arsenic and All-trans Retinoid Acid | acute myeloid leukemia | Tretinoin (NPC317177) | NP level |
| NCT00005823 | Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | leukemia;myelodysplastic syndrome;myeloproliferative disorder | Tretinoin (NPC317177) | NP level |
| NCT00326170 | Phase II 5-Azacytidine Plus VPA Plus ATRA | acute myeloid leukemia;myelodysplastic syndrome | Tretinoin (NPC317177) | NP level |
| NCT00617409 | To Immunize Patients With Extensive Stage SCLC Combined With Chemo With or Without All Trans Retinoic Acid | small cell lung carcinoma | Tretinoin (NPC317177) | NP level |
| NCT00151242 | Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia | acute myeloid leukemia | Tretinoin (NPC317177) | NP level |
| NCT00919191 | Evaluation of Irritation by Two Facial Gels Applied to Opposite Sides of the Face | acne | Tretinoin (NPC317177) | NP level |
| NCT00504764 | Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) | acute promyelocytic leukemia | Tretinoin (NPC317177) | NP level |
| NCT02273102 | Study of TCP-ATRA for Adult Patients With AML and MDS | acute myeloid leukemia;myelodysplastic syndrome | Tretinoin (NPC317177) | NP level |
| NCT03304288 | The Combination of Low-dose Rituximab and ATRA as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia | autoimmune thrombocytopenic purpura | Tretinoin (NPC317177) | NP level |
| NCT00823901 | Safety and Efficacy Study of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel to Treat Rosacea | rosacea | Tretinoin (NPC317177) | NP level |
| NCT01064570 | AIDA 2000 Guidelines | acute promyelocytic leukemia | Tretinoin (NPC317177) | NP level |
| NCT00006220 | Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy | multiple myeloma;leukemia;myelodysplastic syndrome | Tretinoin (NPC317177) | NP level |
| NCT01929278 | W0265-103: A Single-Center, Evaluator-Blinded, Randomized, Placebo Controlled, Phase 1 Clinical Trial Evaluating The Phototoxic Potential Of Topically Applied Clindamycin 1.0% - Tretinoin 0.025% Gel (Ct Gel) In Healthy Volunteers | acne | Tretinoin (NPC317177) | NP level |
| NCT05016349 | Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer. | breast cancer | Tretinoin (NPC317177) | NP level |
| NCT02401295 | ATRA, Celecoxib, and Itraconazole as Maintenance | multiple myeloma | Tretinoin (NPC317177) | NP level |
| NCT00528450 | Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia | leukemia | Tretinoin (NPC317177) | NP level |
| NCT01422785 | A Study Comparing Combination Clindamycin Phosphate/Tretinoin Gel Alone Versus With Benzoyl Peroxide Foaming Cloths for Facial Acne | acne | Tretinoin (NPC317177) | NP level |
| NCT01041833 | Effect of All-trans Retinoic Acid With Chemotherapy Based on Paclitaxel and Cisplatin As First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer and Expression of RAR-alfa and RAR-beta as Response Biomarker | non-small cell lung carcinoma | Tretinoin (NPC317177) | NP level |
| NCT02249767 | Bioequivalence Study of Tretinoin Gel 0.05% to Brand Tretinoin Gel | acne | Tretinoin (NPC317177) | NP level |
| NCT03427554 | To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.1% and RLD in the Treatment of Acne Vulgaris | acne | Tretinoin (NPC317177) | NP level |
| NCT00939133 | Proof of Concept Study to Investigate the Recurrence of Acne Post Isotretinoin | acne | Tretinoin (NPC317177) | NP level |
| NCT01313728 | A Study That Evaluates the Decrease in Irritation When Using Additional Acne Treatment Products | acne | Tretinoin (NPC317177) | NP level |
| NCT02751255 | Daratumumab in Combination With ATRA | multiple myeloma | Tretinoin (NPC317177) | NP level |
| NCT00621218 | A Study to Determine the Safety and Efficacy of Atralin (Tretinoin 0.05%) Gel for the Treatment of Rosacea | rosacea | Tretinoin (NPC317177) | NP level |
| NCT03624270 | Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic Leukaemia | acute promyelocytic leukemia | Tretinoin (NPC317177) | NP level |
| NCT00003601 | Tretinoin With or Without Fenretinide in Treating Patients With Dysplastic Nevus Syndrome | cutaneous melanoma | Tretinoin (NPC317177) | NP level |
| NCT05461755 | Treatment of Striae Distensae With Fractional Radiofrequency and Topical Tretinoin | Striae distensae | Tretinoin (NPC317177) | NP level |
| NCT04724473 | A Study Comparing Tretinoin Cream 0.025% and RETIN-A® Cream 0.025% in the Treatment of Acne Vulgaris | acne | Tretinoin (NPC317177) | NP level |
| NCT02403778 | Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma | melanoma | Tretinoin (NPC317177) | NP level |
| NCT00240513 | Study Comparing Acne in Patients Taking Oral Minocycline to Patients Taking Minocycline Plus Topical Tretinoin | acne | Tretinoin (NPC317177) | NP level |
| NCT03031249 | Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia | acute myeloid leukemia | Tretinoin (NPC317177) | NP level |
| NCT02717884 | Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP) | acute myeloid leukemia;myelodysplastic syndrome | Tretinoin (NPC317177) | NP level |
| NCT00413166 | All-trans Retinoic Acid, and Arsenic +/- Idarubicin | acute promyelocytic leukemia | Tretinoin (NPC317177) | NP level |
| NCT00472966 | Efficacy and Safety of Therapy With Tri-Luma® Cream in Sequence With Glycolic Acid Peels for Melasma | freckles | Tretinoin (NPC317177) | NP level |
| NCT00492856 | S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia | leukemia | Tretinoin (NPC317177) | NP level |
| NCT03392623 | DNA Methylation in Malar Melasma and Its Change by Sunscreen, Retinoic Acid and Niacinamide. | freckles | Tretinoin (NPC317177) | NP level |
| NCT05175508 | Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS | acute myeloid leukemia;myelodysplastic syndrome | Tretinoin (NPC317177) | NP level |
| NCT00835198 | Dapsone Gel 5% and Tretinoin Gel 0.025% Versus Tretinoin Gel 0.025% Monotherapy for Facial Acne Vulgaris | acne | Tretinoin (NPC317177) | NP level |
| NCT04618328 | A Study of ATRA in the Treatment of ITP | autoimmune thrombocytopenic purpura | Tretinoin (NPC317177) | NP level |
| NCT00907335 | A Study of Acne Treatment in Children Ages 9 to 11 | acne | Tretinoin (NPC317177) | NP level |
| NCT01243450 | Bioequivalence Study of Generic Tretinoin 0.04% Microsphere Gel, 0.04% Retin-A Micro® and Placebo | acne | Tretinoin (NPC317177) | NP level |
| NCT00907257 | A Study of Different Use Regimens Using Two Acne Treatments | acne | Tretinoin (NPC317177) | NP level |
| NCT00016159 | Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia | leukemia | Tretinoin (NPC317177) | NP level |
| NCT01067274 | ALFA-0703 Study in Older Patients With Acute Myeloblastic Leukemia (AML) | acute myeloid leukemia | Tretinoin (NPC317177) | NP level |
| NCT04217148 | The Combination of ATRA and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia | autoimmune thrombocytopenic purpura | Tretinoin (NPC317177) | NP level |
| NCT01135069 | Bioequivalence Study of Generic Tretinoin 0.1% Microsphere Gel, 0.1% Retin-A Micro® and Placebo | acne | Tretinoin (NPC317177) | NP level |
| NCT01047189 | Adherence to Study Medication Compared to Generic Topical Clindamycin Plus Generic Topical Tretinoin in Subjects With Mild to Moderate Acne Vulgaris | acne | Tretinoin (NPC317177) | NP level |
| NCT05497310 | Effectiveness and Safety of Therapy Based on Attenuated ATO Plus Low-Dose ATRA in Patients With APL | acute promyelocytic leukemia | Tretinoin (NPC317177) | NP level |
| NCT00195156 | Treatment With ATRA-IV and Depakote in Patients With Advanced Solid Tumor Malignancies | neoplasm | Tretinoin (NPC317177) | NP level |
| NCT01448733 | Safety and Tolerability of Acanya Gel in Combination With Atralin Gel for Acne Vulgaris | acne | Tretinoin (NPC317177) | NP level |
| NCT01226303 | Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia | acute promyelocytic leukemia | Tretinoin (NPC317177) | NP level |
| NCT02842827 | IMG-7289, With and Without ATRA, in Patients With Advanced Myeloid Malignancies | acute myeloid leukemia;myelodysplastic syndrome | Tretinoin (NPC317177) | NP level |
| NCT02899169 | Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF) | acute promyelocytic leukemia | Tretinoin (NPC317177) | NP level |
| NCT00378365 | Acute Promyelocytic Leukemia 2006 (APL) | acute promyelocytic leukemia | Tretinoin (NPC317177) | NP level |
| NCT00838812 | Safety and Efficacy Study of Association Between Tretinoin and Clindamycin on the Treatment of Acne Mild and Moderate | acne | Tretinoin (NPC317177) | NP level |
| NCT01048645 | Effect of All-trans Retinoic Acid With Chemotherapy Based in Paclitaxel and Cisplatin as First Line Treatment of Patients With Advanced Non-small Cell Lung Cancer | non-small cell lung carcinoma | Tretinoin (NPC317177) | NP level |
| NCT00514293 | Bexarotene, Tretinoin, and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | lung cancer | Tretinoin (NPC317177) | NP level |
| NCT01206348 | Combination Treatment for Moderate to Severe Acne | acne | Tretinoin (NPC317177) | NP level |
| NCT00382200 | Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes | myelodysplastic syndrome | Tretinoin (NPC317177) | NP level |
| NCT00551460 | S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia | leukemia | Tretinoin (NPC317177) | NP level |
| NCT04396067 | Aerosol Combination Therapy of All-trans Retinoic Acid and Isotretinoin as A Novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients Better Than Vaccine : An Innovative Treatment | COVID-19 | Tretinoin (NPC317177) | NP level |
| NCT02177812 | A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia (AML) | leukemia | Tretinoin (NPC317177) | NP level |
| NCT00892190 | Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome | acute myeloid leukemia;myelodysplastic syndrome | Tretinoin (NPC317177) | NP level |
| NCT01404949 | Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy | acute promyelocytic leukemia | Tretinoin (NPC317177) | NP level |
| NCT00146120 | Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result | acute myeloid leukemia | Tretinoin (NPC317177) | NP level |
❱❱❱ Associated Human Diseases and Detailed Association Evidence
How do we define the Plant-Targeted Human Disease Association?
Associated human diseases of an individual plant are summurized based on FOUR types of association evidence, these include:
❶ Association by Therapeutic Target: Bioactive protein targets of the plant were defined in "Molecular Targets" section, target-disease associations collected from TTD database were subsequently used to build the associations between the plant and its targeted human diseases.
❷ Association by Disease Gene Reversion: Plant and a specific disease will be associated when >= 1 plant target gene overlaped with disease's DEGs.
❸ Association by Clinical Trials of Plant: Plant and a specific disease will be associated when >= 1 clinical trial (the plant is the intervetion) can be matched in ClinicalTrials.gov database.
❹ Association by Clinical Trials of Plant Ingredients: Plant and a specific disease will be associated when >= 1 clinical trial (the plant ingredient is the intervetion) can be matched in ClinicalTrials.gov database.
Associated Disease of the Plant |
Association Type & Detailed Evidence |
|---|---|
Adenocarcinoma of pancreasDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C10.0 |
HIF1A,RARB,BLM,RARG,HTR2B,APP,RARA
|
Germ cell tumour of testisDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C80.2 |
HIF1A,SMN1,MAPK1,BLM,RARG,APP,RXRG
|
Lung cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C25 |
PIN1,RXRG,RORC
NCT00601796,NCT00005825,NCT00514293 |
Solid tumour/cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A00-2F9Z |
MAPK1,HIF1A,RXRG,APP,RORC,RARA
|
Mature T-cell lymphomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A90 |
RARA,RARB,HIF1A
NCT00002479,NCT00005969 |
MelanomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C30 |
MAPK1
NCT04303169,NCT03200847,NCT02403778,NCT04305041 |
Kaposi sarcomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B57 |
RARB,RXRG,RXRB,RARG,RXRA
|
FrecklesDisease Category: 14.Diseases of the skinDisease ICD-11 Code: ED61.0 |
NCT00469183,NCT03392623,NCT00472966,NCT00717652,NCT00669071
|
Immune thrombocytopenic purpuraDisease Category: 03.Diseases of the blood or blood-forming organsDisease ICD-11 Code: 3B64.10 |
NCT03304288,NCT04217148,NCT01882127,NCT04618328,NCT05438875
|
Multiple myelomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A83 |
NCT00006220,NCT04700176,NCT02751255,NCT01985477,NCT02401295
|
PheochromocytomaDisease Category: X.Extension CodesDisease ICD-11 Code: XH3854 |
RORC,BLM,APP,RARA,RXRG
|
Diffuse large B-cell lymphomasDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A81 |
RARB,SMN1,BLM,PIN1,HTR2B
|
Acne vulgarisDisease Category: 14.Diseases of the skinDisease ICD-11 Code: ED80 |
RARG
NCT00939133,NCT01313728,NCT01243450,NCT00952523,NCT01047189,NCT00919191,NCT00907335,NCT01422785,NCT04883736,NCT00714714,NCT00689117,NCT01206348,NCT00240513,NCT01135069,NCT02249767,NCT03427554,NCT04724473,NCT03433378,NCT01522456,NCT01929278,NCT00841776,NCT01448733,NCT00835198,NCT02620813,NCT04548349,NCT00907257,NCT00891982,NCT01915758,NCT01111994,NCT00838812 |
Alzheimer diseaseDisease Category: 08.Diseases of the nervous systemDisease ICD-11 Code: 8A20 |
APP,RARA,RARB
|
Neuroblastoma, NOSDisease Category: X.Extension CodesDisease ICD-11 Code: XH85Z0 |
NCT00017225,NCT00533169,NCT02641782
|
RosaceaDisease Category: 14.Diseases of the skinDisease ICD-11 Code: ED90 |
NCT00823901,NCT00621218,NCT01125930
|
Non-small cell lung cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C25 |
NCT04919369,NCT01048645,NCT01041833
|
Serous cystadenoma,borderline malignancy of ovaryDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C73.4 |
RARG,RORC,RXRG
|
Malignant neoplasms of biliary tract, distal bile ductDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C15 |
HIF1A,BLM,RARG
|
HepatoblastomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C12.01 |
BLM,RARG,RXRG
|
Carpal tunnel syndromeDisease Category: 08.Diseases of the nervous systemDisease ICD-11 Code: 8C10.0 |
HTR2B,RARA,RXRG
|
Acute myeloid leukaemiaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A60 |
RARA,RARG
NCT00143975,NCT00146120,NCT00962767,NCT00867672,NCT05175508,NCT00136461,NCT05297123,NCT01067274,NCT02717884,NCT04282668,NCT02261779,NCT01237808,NCT00326170,NCT01575691,NCT00175812,NCT00892190,NCT01161550,NCT02842827,NCT00151255,NCT03356080,NCT00151242,NCT02273102,NCT02942758,NCT03031249 |
Acute promyelocytic leukaemiaDisease Category: X.Extension CodesDisease ICD-11 Code: XH1A50 |
NCT05497310,NCT02020161,NCT04793919,NCT01064570,NCT00003934,NCT01409161,NCT02899169,NCT02339740,NCT02200978,NCT01226303,NCT00180128,NCT01404949,NCT00378365,NCT03624270,NCT00866918,NCT00599937,NCT00408278,NCT02688140,NCT00504764,NCT00413166
|
Pulmonary hypertensionDisease Category: 11.Diseases of the circulatory systemDisease ICD-11 Code: BB01 |
HIF1A,HTR2B
|
Pancreatic cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C10 |
MAPK1,RXRG
|
Muscular atrophyDisease Category: 08.Diseases of the nervous systemDisease ICD-11 Code: 8B61 |
SMN1,SMN2
|
PsoriasisDisease Category: 14.Diseases of the skinDisease ICD-11 Code: EA90 |
RARG,RORC
|
EmphysemaDisease Category: 12.Diseases of the respiratory systemDisease ICD-11 Code: CA21 |
RARG
NCT00000621 |
Breast cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C60-2C6Y |
RXRG
NCT05016349 |
Myeloproliferative neoplasmDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A20 |
NCT00005863,NCT00005823
|
Primary sclerosing cholangitisDisease Category: 13.Diseases of the digestive systemDisease ICD-11 Code: DB96.2 |
NCT01456468,NCT03359174
|
Malignant neoplasms of kidney, except renal pelvisDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C90 |
NCT00100906,NCT00003656
|
Carcinosarcoma of uterusDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C76.43 |
RORC,RXRG
|
Melanoma of skinDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C30 |
RARB,APP
|
Hepatocellular carcinoma of liverDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C12.02 |
BLM,RXRG
|
Adenocarcinoma of bronchus or lungDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C25.0 |
BLM,HTR2B
|
Glioblastoma of brainDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A00.00 |
BLM,RARA
|
Myelodysplastic syndromeDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A37 |
RARA
NCT03356080,NCT00326170,NCT05175508,NCT00136461,NCT03259516,NCT00382200,NCT00439673,NCT02842827,NCT00006239,NCT00892190,NCT00006220,NCT00005823,NCT02273102,NCT02717884,NCT01575691,NCT00005863 |
LeukaemiaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A60-2B33 |
NCT00276601,NCT00016159,NCT00006239,NCT00006220,NCT00005823,NCT00002658,NCT02177812,NCT00005863,NCT00002701,NCT00492856,NCT00528450,NCT00482833,NCT00551460
|
Dystrophic epidermolysis bullosaDisease Category: 14.Diseases of the skinDisease ICD-11 Code: EC32 |
APP
|
DepressionDisease Category: 06.Mental, behavioural or neurodevelopmental disordersDisease ICD-11 Code: 6A70-6A7Z |
HTR2B
|
Brain cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A00 |
HIF1A
|
Adrenomedullary hyperfunctionDisease Category: 05.Endocrine, nutritional or metabolic diseasesDisease ICD-11 Code: 5A75 |
HIF1A
|
Diagnostic imagingDisease Category: NADisease ICD-11 Code: N.A. |
APP
|
Multiple sclerosisDisease Category: 08.Diseases of the nervous systemDisease ICD-11 Code: 8A40 |
RORC
|
RetinopathyDisease Category: 09.Diseases of the visual systemDisease ICD-11 Code: 9B71 |
APP
|
Arteries/arterioles disorderDisease Category: 11.Diseases of the circulatory systemDisease ICD-11 Code: BD52 |
MAPK1
|
Muscle calcification/ossificationDisease Category: 15.Diseases of the musculoskeletal system or connective tissueDisease ICD-11 Code: FB31 |
RARG
|
Pituitary gland disorderDisease Category: 05.Endocrine, nutritional or metabolic diseasesDisease ICD-11 Code: 5A60-5A61 |
HTR2B
|
Prostate cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C82 |
RXRG
|
Psychotic disorderDisease Category: 06.Mental, behavioural or neurodevelopmental disordersDisease ICD-11 Code: 6A20-6A25 |
HTR2B
|
KinetoplastidsDisease Category: 01.Certain infectious or parasitic diseasesDisease ICD-11 Code: 1F61-1G2Z |
RXRG
|
Autoimmune diseaseDisease Category: 04.Diseases of the immune systemDisease ICD-11 Code: 4A40-4A45 |
RORC
|
Nasopharyngeal cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B6B |
PIN1
|
Desmoid tumourDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2F7C |
APP
|
Acute diabete complicationDisease Category: 05.Endocrine, nutritional or metabolic diseasesDisease ICD-11 Code: 5A2Y |
RXRG
|
Attention deficit hyperactivity disorderDisease Category: 06.Mental, behavioural or neurodevelopmental disordersDisease ICD-11 Code: 6A05 |
HTR2B
|
Crohn diseaseDisease Category: 13.Diseases of the digestive systemDisease ICD-11 Code: DD70 |
RORC
|
Mycosis fungoidesDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B01 |
RXRA
|
Light sensitivity impairmentDisease Category: 09.Diseases of the visual systemDisease ICD-11 Code: 9D45 |
RXRG
|
AmyloidosisDisease Category: 05.Endocrine, nutritional or metabolic diseasesDisease ICD-11 Code: 5D00 |
APP
|
NeoplasmsDisease Category: 02.NeoplasmsDisease ICD-11 Code: 02 |
NCT00195156
|
Malignant neoplasm of pancreas, unspecifiedDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C10.Z |
NCT04241276
|
VasculitisDisease Category: 04.Diseases of the immune systemDisease ICD-11 Code: 4A44 |
NCT01275274
|
Squamous cell carcinomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B60-2D01 |
NCT00007631
|
Actinic keratosisDisease Category: X.Extension CodesDisease ICD-11 Code: XH36H6 |
NCT02278861
|
Amyotrophic lateral sclerosisDisease Category: 08.Diseases of the nervous systemDisease ICD-11 Code: 8B60.0 |
NCT00919555
|
COVID-19Disease Category: 01.Certain infectious or parasitic diseasesDisease ICD-11 Code: 1D6Y |
NCT04396067
|
ThrombocytopeniaDisease Category: 03.Diseases of the blood or blood-forming organsDisease ICD-11 Code: 3B64 |
NCT01667263
|
Melanoma of skin, unspecifiedDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C30.Z |
NCT00003601
|
Lentigo malignaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2E63.00 |
NCT00975312
|
Adenoid cystic carcinomaDisease Category: X.Extension CodesDisease ICD-11 Code: XH4302 |
NCT03999684
|
Adenocarcinoma of prostateDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C82.0 |
NCT03572387
|
Stretch marksDisease Category: 14.Diseases of the skinDisease ICD-11 Code: EE40.1 |
NCT05461755
|
AnemiaDisease Category: 03.Diseases of the blood or blood-forming organsDisease ICD-11 Code: 3A00-3A9Z |
NCT04324411
|
Basal cell carcinomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C32 |
NCT00007631
|
Small cell carcinoma of bronchus or lungDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C25.1 |
NCT00617409
|
HypercholesterolaemiaDisease Category: 05.Endocrine, nutritional or metabolic diseasesDisease ICD-11 Code: 5C80.0 |
NCT02497833
|
Neoplasms of unknown behaviour of breastDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2F95 |
NCT04113863
|
Malignant haematopoietic neoplasmDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B33 |
NCT02712905
|
Myeloproliferative and myelodysplastic disease, unclassifiableDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A44 |
NCT00006239
|
Autism spectrum disorderDisease Category: 06.Mental, behavioural or neurodevelopmental disordersDisease ICD-11 Code: 6A02 |
NCT05281965
|
LeishmaniasisDisease Category: 01.Certain infectious or parasitic diseasesDisease ICD-11 Code: 1F54 |
BLM
|
Adenocarcinoma of stomachDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B72.0 |
BLM
|
Squamous cell carcinoma of bronchus or lungDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C25.2 |
BLM
|
Mesothelioma of pleuraDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C26.0 |
SMN1
|
Tetralogy of FallotDisease Category: 20.Developmental anomaliesDisease ICD-11 Code: LA88.2 |
RORC
|
Malignant neoplasms of oesophagusDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B70 |
BLM
|
Urothelial carcinoma of bladderDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C94.2 |
BLM
|
Malignant neoplasms of thyroid gland, unspecifiedDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2D10.Z |
RXRG
|
Malignant neoplasms of corpus uteri, unspecifiedDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C76.Z |
BLM
|
Chikungunya virus diseaseDisease Category: 01.Certain infectious or parasitic diseasesDisease ICD-11 Code: 1D40 |
HIF1A
|
Polycystic ovary syndromeDisease Category: 05.Endocrine, nutritional or metabolic diseasesDisease ICD-11 Code: 5A80.1 |
RXRG
|
Malignant neoplasms of thymusDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C27 |
PIN1
|
Invasive carcinoma of breastDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C61 |
BLM
|
Malignant neoplasms of adrenal glandDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2D11 |
BLM
|
Gliomas of brainDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A00.0 |
BLM
|
❱❱❱ Network Visualization of Plant-Targeted Human Disease Associations
Plant-Targeted Human Disease Network
>> Targets derived from weak experimental activities
